An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids

Trial Profile

An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Feb 2016 Status changed from recruiting to withdrawn prior to enrolment as per the ClinicalTrials.gov record.
    • 14 Oct 2014 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017, as reported by Clinicaltrials.gov record,
    • 14 Oct 2014 Status changed from not yet recruiting to recruiting, as reported by Clinicaltrials.gov record,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top